UB Paderborn / Katalog / Suche / in CDI

1 – 11 von 11

Sortiert nach

Risk of relapse in patients receiving azithromycin after allogeneic HSCT

Bone marrow transplantation (Basingstoke), 2021-04, Vol.56 (4), p.960-962

2021

Volltextzugriff (PDF)

Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics

Journal of oncology pharmacy practice, 2023-10, p.10781552231208442-10781552231208442

2023

Volltextzugriff (PDF)

Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer

Breast cancer research and treatment, 2014-12, Vol.148 (3), p.571-580

2014

Volltextzugriff (PDF)

Abstract PS7-49: Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS7-49-PS7-49

2021

Volltextzugriff (PDF)

Abstract P3-23-05: Evaluation of CDK 4/6 inhibitor practice patterns and institutional versus national adherence to palbociclib laboratory monitoring in breast cancer patients

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P3-P3-23-05

2022

Volltextzugriff (PDF)

Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?

Expert opinion on drug safety, 2020-08, Vol.19 (8), p.923-926

2020

Volltextzugriff (PDF)

Building a robust pharmacy research program: Reflections from a large healthcare system not affiliated with a college of pharmacy

JAACP : Journal of the American College of Clinical Pharmacy, 2024-07, Vol.7 (7), p.647-658

2024

Volltextzugriff (PDF)

Abstract P4-07-56: Mayo Clinic Enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P4-P4-07-56

2023

Volltextzugriff (PDF)

Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT1-04-02-OT1-04-02

2023

Volltextzugriff (PDF)

Abstract P4-01-22: Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P4-P4-01-22

2023

Volltextzugriff (PDF)

Relapse Rates in Patients Receiving Azithromycin for the Treatment of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplant

Biology of blood and marrow transplantation, 2019-03, Vol.25 (3), p.S286-S286

2019

Volltextzugriff (PDF)

1 – 11 von 11

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(10)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(11)

Sprache

Englisch
(11)

Erscheinungsjahr

n.n

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk of relapse in patients receiving azithromycin after allogeneic HSCT

Development of oral oncolytic nonadherence estimator (ORACLE): A pretreatment nonadherence risk assessment for oral oncolytics

Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer

Abstract PS7-49: Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancer

Abstract P3-23-05: Evaluation of CDK 4/6 inhibitor practice patterns and institutional versus national adherence to palbociclib laboratory monitoring in breast cancer patients

Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?

Building a robust pharmacy research program: Reflections from a large healthcare system not affiliated with a college of pharmacy

Abstract P4-07-56: Mayo Clinic Enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer

Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Abstract P4-01-22: Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience

Relapse Rates in Patients Receiving Azithromycin for the Treatment of Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplant

Suchergebnisse filtern